Meyenburg Prize for Michel Sadelain – Award ceremony at the Cancer Research Award Symposium on April 2, 2025
On April 2, 2025 at 15:30, the Meyenburg Prize will be awarded at the German Cancer Research Center (DKFZ) in Heidelberg. This year, Michel Sadelain will be honored at the Cancer Research Award Symposium of the Meyenburg Foundation. His research has revolutionized cancer therapy by using the immune system to target malignant cells. With the development of chimeric antigen receptor (CAR) T cells, Michel Sadelain has fundamentally changed the treatment of certain cancers.
Stefan Fröhling (Managing Director at the NCT Heidelberg, Head of the Division of Translational Medical Oncology at the DKFZ and Member of the Board of the Meyenburg Foundation) says: “From the initial concept to approval in 2017, Michel Sadelain's work represents one of the most significant breakthroughs in modern oncology – and gives hope to patients who previously had none.”
In addition to the award ceremony, participants can look forward to a high-level scientific symposium with experts in cancer research. The speakers are:
- Michel Sadelain, Columbia University, New York
- Andreas Mackensen, University Hospital Erlangen
- Fabrice André, Institut Gustave Roussy
- Hafsa Munir, DKFZ and Helmholtz Institute for Translational Oncology (HI-TRON) Mainz
- Franziska Blaeschke, DKFZ and Hopp Children's Cancer Center (KiTZ) Heidelberg
Those interested can register until March 28. Further information on the program and registration can be found at the following link: https://indico.dkfz.de/e/MeyenburgCancerResearchAward2025
The Meyenburg Foundation, under the umbrella of the German Cancer Research Center, has been awarding the Meyenburg Prize since 1981. The award, which is given annually for outstanding achievements in the field of cancer research, is one of the most highly endowed science prizes in Germany, worth 50,000 euros.
Meyenburg Prize for Michel Sadelain – Award ceremony at the Cancer Research Award Symposium on April 2, 2025
On April 2, 2025 at 15:30, the Meyenburg Prize will be awarded at the German Cancer Research Center (DKFZ) in Heidelberg. This year, Michel Sadelain will be honored at the Cancer Research Award Symposium of the Meyenburg Foundation. His research has revolutionized cancer therapy by using the immune system to target malignant cells. With the development of chimeric antigen receptor (CAR) T cells, Michel Sadelain has fundamentally changed the treatment of certain cancers.
Stefan Fröhling (Managing Director at the NCT Heidelberg, Head of the Division of Translational Medical Oncology at the DKFZ and Member of the Board of the Meyenburg Foundation) says: “From the initial concept to approval in 2017, Michel Sadelain's work represents one of the most significant breakthroughs in modern oncology – and gives hope to patients who previously had none.”
In addition to the award ceremony, participants can look forward to a high-level scientific symposium with experts in cancer research. The speakers are:
- Michel Sadelain, Columbia University, New York
- Andreas Mackensen, University Hospital Erlangen
- Fabrice André, Institut Gustave Roussy
- Hafsa Munir, DKFZ and Helmholtz Institute for Translational Oncology (HI-TRON) Mainz
- Franziska Blaeschke, DKFZ and Hopp Children's Cancer Center (KiTZ) Heidelberg
Those interested can register until March 28. Further information on the program and registration can be found at the following link: https://indico.dkfz.de/e/MeyenburgCancerResearchAward2025
The Meyenburg Foundation, under the umbrella of the German Cancer Research Center, has been awarding the Meyenburg Prize since 1981. The award, which is given annually for outstanding achievements in the field of cancer research, is one of the most highly endowed science prizes in Germany, worth 50,000 euros.